Evidence map›Paper›PMID 31220185›Full record

ArticlePloS one2019

Characterization of Brucella canis infection in mice.

Lauren W Stranahan, Omar H Khalaf, Daniel G Garcia-Gonzalez, Angela M Arenas-Gamboa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. OralFrontiers in microbiology · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Uncovering the Hidden Credentials ofMicrobiology and molecular biology reviews : MMBR · 2021
    Review
  9. Epitope-Based Vaccine of aFrontiers in immunology · 2021
    Article
  10. When the Going Gets Rough: The Significance ofFrontiers in microbiology · 2021
    Review
  11. Deletion of the Transcriptional Regulator MucR inFrontiers in veterinary science · 2021
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Lauren W StranahanDepartment of Veterinary Pathobiology, Texas A&M University, College of Veterinary Medicine, College Station, TX, United States of America.ORCID 0000-0002-0746-5949
Omar H KhalafDepartment of Veterinary Pathobiology, Texas A&M University, College of Veterinary Medicine, College Station, TX, United States of America.
Daniel G Garcia-GonzalezDepartment of Veterinary Pathobiology, Texas A&M University, College of Veterinary Medicine, College Station, TX, United States of America.
Angela M Arenas-GamboaDepartment of Veterinary Pathobiology, Texas A&M University, College of Veterinary Medicine, College Station, TX, United States of America.
Texas A&M University · USUniversity of Baghdad · IQ

Funding

Use of the goat model to test human Brucella vaccines in ArgentinaK01TW009981 · FIC · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ARENAS, ANGELA M · 2014 to 2018
$670k
FIC NIH HHS K01 TW009981
6 · The paper itself

Abstract

Canine brucellosis, caused by Brucella canis, is a disease of dogs and represents a public health concern as it can be transmitted to humans. Canine brucellosis is on the rise in the United States and there is currently no vaccine for use in dogs. Mice have been extensively utilized to investigate host-pathogen interactions and vaccine candidates for smooth Brucella species and could serve a similar role for studying B. canis. However, comparatively little is known about B. canis infection in mice. The objective of this study was to characterize the kinetics of colonization and pathogenicity of B. canis in mice in order to evaluate the mouse as a model for studying this pathogen. C57BL/6 mice were inoculated intraperitoneally with 105, 107, or 109 CFU of Brucella canis RM6/66 and euthanized 1-, 2-, 4-, 6-, 9-, and 12-weeks post-inoculation. B. canis induced splenomegaly in mice infected with 109 CFU at 1- and 2 weeks post-inoculation while no gross lesions were observed in other dose groups. Infection at the two higher doses resulted in dose-dependent granulomatous hepatitis and histiocytic infiltration of the spleen and mesenteric lymph nodes by 1-2 weeks. B. canis was cultured from the liver, spleen, uterus, bone marrow, lung, and kidney in all groups with colonization declining at a slow but steady rate throughout the experiment. Clearance was achieved by 9 weeks 105 CFU group and by 12 weeks in the 107 CFU group, while B. canis persisted in the spleen until 12 weeks in the highest dose group. Although B. canis does not demonstrate significant replication in C57BL/6 mice, it has the ability to establish an infection, induce splenomegaly, and persist for several weeks in multiple organs. Moreover, 1 x 107 CFU appears to be a suitable challenge dose for investigating vaccine safety.

Indexed as

AnimalsBrucella canisBrucellosisDisease ProgressionFemaleKineticsMiceMice, Inbred C57BLRodent Diseases

Identifiers

PMID31220185
PMCPMC6586350
OpenAlexW2951086400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.